A recent study published in the Journal of Affective Disorders suggests that deep-seated negative beliefs formed in childhood ...

One dose of synthetic psilocybin in combination with psychotherapy significantly reduces treatment-resistant depression associated with bipolar II disorder (BDII), a small, nonrandomized clinical ...

How 3 new studies use modern science to explore age-old questions and support people living with bipolar disorder today. Key ...

As reviewed in recent posts, bipolar I and bipolar II disorders are associated with substantial functional impairments and increased mortality. Depressive episodes associated with bipolar disorder do ...

A study, published this month in the journal JAMA Psychiatry, sought to determine whether “a single psychedelic dose of psilocybin with psychotherapy demonstrate[s] evidence for efficacy and/or safety ...

A new study led by University of Chicago researchers suggests a significant link between exposure to environmental pollution and an increase in the prevalence of neuropsychiatric disorders. Based on ...

Caplyta (lumateperone) was approved for the treatment of schizophrenia in 2019 and for depressive episodes linked to bipolar I or bipolar II disorder (bipolar depression) in 2021. Caplyta can be used ...